Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort
Open Access
- 23 April 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 25 (9), e1292-e1302
- https://doi.org/10.1634/theoncologist.2020-0249
Abstract
Lessons Learned Bintrafusp alfa had a manageable safety profile and demonstrated preliminary clinical activity in heavily pretreated patients with solid tumors (including hepatocellular carcinoma) with no or limited treatment options. Findings from this study suggest bintrafusp alfa may be a novel therapeutic approach for patients with advanced solid tumors. Additional trials are needed to further explore safety and efficacy of bintrafusp alfa in specific tumor types. Background Bintrafusp alfa is a first‐in‐class bifunctional fusion protein composed of the extracellular domain of transforming growth factor‐β (TGF‐β) RII receptor (a TGF‐β “trap”) fused to a human immunoglobulin (Ig) G1 antibody blocking programmed death‐ligand 1 (PD‐L1). Bintrafusp alfa is designed to neutralize TGF‐β signaling by “trapping” and sequestering all TGF‐β isoforms, and this trap function is physically linked to PD‐L1 blockade in the tumor microenvironment. Methods NCT02699515 was a phase I, open‐label, dose‐escalation study of bintrafusp alfa (3, 10, and 20 mg/kg every 2 weeks) in Asian patients with advanced solid tumors, including a hepatocellular carcinoma (HCC) safety‐assessment cohort. The primary objective was safety and tolerability; the secondary objective is best overall response. Results As of August 24, 2018, 23 patients (including 9 in the HCC cohort) received bintrafusp alfa. Eight patients experienced treatment‐related adverse events (TRAEs). Three patients had grade 3 TRAEs (13.0%; hypoacusis, hyponatremia, hypopituitarism, increased blood creatine phosphokinase, and intracranial tumor hemorrhage); one had grade 4 hyponatremia (4.3%). No treatment‐related deaths occurred. In the dose‐escalation cohort, two patients had a confirmed partial response, and 3 had stable disease (SD), for an overall response rate of 14.3% and a disease control rate (DCR) of 35.7%. In the HCC cohort, one patient had SD (DCR, 11.1%). A dose‐proportional pharmacokinetics profile was observed at doses of >3 mg/kg. Conclusion Bintrafusp alfa had a manageable safety profile and preliminary efficacy in heavily pretreated patients with advanced solid tumors, including HCC.Keywords
This publication has 20 references indexed in Scilit:
- Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid TumorsClinical Cancer Research, 2018
- Mechanisms of resistance to immune checkpoint inhibitorsBritish Journal of Cancer, 2018
- PD-L1 inhibitors in the pipeline: Promise and progressOncoImmunology, 2017
- A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cellsOncoImmunology, 2017
- Immune Checkpoint Blockade in Cancer TherapyJournal of Clinical Oncology, 2015
- Targeting the TGFβ signalling pathway in diseaseNature Reviews Drug Discovery, 2012
- Frequency of Deletions of EPCAM (TACSTD1) in MSH2-Associated Lynch Syndrome CasesThe Journal of Molecular Diagnostics, 2011
- Contextual Regulation of Inflammation: A Duet by Transforming Growth Factor-β and Interleukin-10Immunity, 2008
- Mechanisms of TGF-β Signaling from Cell Membrane to the NucleusCell, 2003
- Pituitary apoplexy: its incidence and clinical significanceJournal of Neurosurgery, 1981